The estimated Net Worth of K Peony Yu is at least $16.6 Milión dollars as of 15 June 2023. Kin Yu owns over 1,709 units of FibroGen Inc stock worth over $1,114 and over the last 10 years he sold FGEN stock worth over $10,764,887. In addition, he makes $5,856,450 as Chief Medical Officer at FibroGen Inc.
Kin has made over 55 trades of the FibroGen Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 1,709 units of FGEN stock worth $684 on 15 June 2023.
The largest trade he's ever made was selling 40,000 units of FibroGen Inc stock on 2 October 2017 worth over $2,185,200. On average, Kin trades about 4,178 units every 33 days since 2014. As of 15 June 2023 he still owns at least 2,786 units of FibroGen Inc stock.
You can see the complete history of Kin Yu stock trades at the bottom of the page.
Dr. Kin-Hung Peony Yu serves as Chief Medical Officer of the Company.D., is Chief Medical Officer of the Company. She served as our Vice President of Clinical Development from December 2008 until April 2016 when she was promoted to Chief Medical Officer. Dr. Yu brings to us expertise in design and execution of all phases of clinical development programs, including clinical and regulatory strategy, interactions with regulatory authorities in the United States and European Union, as well as experience with successful leadership of clinical teams. Prior to joining us, Dr. Yu was Vice President of Clinical Research at Anesiva, Inc., where she was responsible for management of clinical research, statistics/data management, clinical operations, and medical affairs/medical information for all clinical programs, including the late-stage clinical development and approval of Zingo®, a drug-device combination for pain management. Prior to Anesiva, Dr. Yu was Director, Clinical Development at ALZA Corporation (a subsidiary of Johnson & Johnson) where she was Global Clinical Lead for IONSYS®, a drug-device combination for post-operative pain, and led a successful New Drug Application resubmission with the U.S. Food and Drug Administration and multiple interactions with European regulatory authorities resulting in marketing approval in 25 European countries. Prior to ALZA, Dr. Yu held previous posts at Pain Therapeutics, Inc. and at Elan Pharmaceuticals. Dr. Yu received a Bachelor of Science degree in Chemical Engineering and a medical degree both from the University of California, Davis, followed by residency training at Stanford Medical School.
As the Chief Medical Officer of FibroGen Inc, the total compensation of Kin Yu at FibroGen Inc is $5,856,450. There are no executives at FibroGen Inc getting paid more.
Kin Yu is 57, he's been the Chief Medical Officer of FibroGen Inc since 2016. There are 13 older and 8 younger executives at FibroGen Inc. The oldest executive at FibroGen Inc is Thomas Kearns, 83, who is the Lead Independent Director.
K's mailing address filed with the SEC is 25651, Atlantic Ocean Drive, Lake Forest, Orange County, California, 92630, United States.
Over the last 10 years, insiders at FibroGen Inc have traded over $188,593,537 worth of FibroGen Inc stock and bought 106,523 units worth $1,309,423 . The most active insiders traders include Rory B Riggs, Thomas B Neff a Jeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,963. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth $25,884.
fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
FibroGen Inc executives and other stock owners filed with the SEC include: